

PRESS RELEASE

FOR IMMEDIATE RELEASE

Haitong International Successfully Completed an IPO deal for Genscript Biotech Corporation

Hong Kong, 4 January 2016 – Haitong International Securities Group Limited (“Haitong International”; Stock Code: 665.HK) is pleased to announce that it has completed an IPO deal for Genscript Biotech Corporation (“Genscript Biotech”, 1548.HK) on 30 December with gross proceeds of around USD 67 million. Haitong International acted as the Sole Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager to assist the company in the IPO deal and successfully raising funding from the equity market.

Genscript Biotech is a well-recognized life sciences research and application service and product provider with comprehensive portfolio coverage in the world.

Haitong International has already completed 17 IPO deals so far this year.

– END –

Haitong International Securities Group Limited

Haitong International Securities Group Limited (“Haitong International”; Stock Code: 665.HK) is an international financial institution with established presence in Hong Kong and a rapidly expanding network across the globe. It strives to serve as a bridge linking up the Chinese and overseas capital markets. Haitong International is a subsidiary of Haitong International Holdings Limited, a company incorporated in Hong Kong and wholly owned by Haitong Securities Co., Ltd. (“Haitong Securities”, Stock Code: 600837.SH; 6837.HK).

To date, Haitong International is well positioned to serve over 190,000 corporate, institutional and retail clients worldwide. Its well-established investment banking business platform provides corporate finance, brokerage and margin financing, asset management, fixed income, currency and commodities (FICC), leveraged and acquisition finance, equity investment and a full spectrum of financial products and services. Haitong International possesses a sound risk management system that is in line with international standards. In 2014, it became the first Chinese financial institution in Hong Kong to have been assigned a “BBB” long-term credit rating by Standard and Poor’s.

Haitong International has more than 10 branches in Hong Kong and Macau and a representative office in each of Beijing and Shanghai. In 2014, Haitong International quickened the pace of overseas expansion by establishing its Singapore subsidiary. It also completed the acquisition of Japaninvest Group plc in March of 2015, setting up a financial servicing network covering the world’s major capital markets including Hong Kong, New York, London, Tokyo.

For further information, please contact:
Haitong International Securities Group Limited

鄧玉珊 Theresa Tang
電話：(852) 2213 8508
電郵：theresa.ys.tang@htisec.com

徐瀟 Ann Xu
電話：(852) 2213 8692
電郵：ann.x.xu@htisec.com

Genscript Biotech Corporation (01548) said its retail offering was over-subscribed by about 4 times and the international offering was